e-ISSN: 2321-3647
logo

American Journal of Pharmacy and Health Research

📢 Latest Update: Call for Papers – Special Issue on Pharmacy and Health Research (April 2026 Submission Deadline)

📢 Latest Update: Call for Papers – Special Issue on Pharmacy and Health Research (April 2026 Submission Deadline)

Volume 8, Issue 6 - 2020 (June 2020 Issue 6)

Volume 8 Issue 6 Cover

Issue Details:

Volume 8 Issue 6
Published:Invalid Date

Editorial: June 2020 Issue 6

Welcome to the 2020 issue of American Journal of Pharmacy and Health Research. This issue showcases the remarkable breadth and depth of contemporary research across multiple disciplines. From cutting-edge applications of machine learning in climate science to the revolutionary potential of quantum computing in drug discovery, our featured articles demonstrate the power of interdisciplinary collaboration in addressing global challenges.

We are particularly excited to present research that bridges traditional academic boundaries, reflecting our journal's commitment to fostering innovation through cross-disciplinary dialogue. The integration of artificial intelligence with environmental science, the application of blockchain technology to supply chain management, and the convergence of urban planning with smart city technologies exemplify the transformative potential of collaborative research.

As we continue to navigate an era of rapid technological advancement and global challenges, the research presented in this issue offers both insights and solutions that will shape our future. We thank our authors, reviewers, and editorial board members for their continued dedication to advancing knowledge and promoting scientific excellence.

Dr. Hemangi J Patel
Editor-in-Chief
American Journal of Pharmacy and Health Research

Articles in This Issue

Showing 4 of 4 articles
Research PaperID: AJPHR806001

Psoriasis pathogenesis and current treatment: A Review

Rohit Kumar, DP Pathak, PK Sahoo

ABSTRACTPsoriasis is a multi-factorial skin disease with a complex pathogenesis. Various factors which have been suggested to play a key role in the pathogenesis are T cells, antigen presenting cells (APC's), keratinocytes, Langerhans' cells, macrophages, natural killer cells, an array of Th1 type cytokines. The age of onset, chronicity, physical, and psychosocial consequences of the disease cause psoriasis to have a significant impact on patient quality of life. Scalp psoriasis is no different, and effective treatment results in an improvement in quality of life. Successful management of scalp psoriasis includes topical therapies that are acceptable to the patient for mild-to-moderate disease, and systemic therapies for recalcitrant or moderate-to-severe disease. The factors influencing psoriasis severity, the indications for systemic treatments, the overall parameters to be considered in the treatment choice, life style interventions, and the recommendations for the use, screening, and monitoring of systemic therapies available including acitretin, cyclosporine, methotrexate, apremilast, adalimumab, etanercept, infliximab. Keywords: Psoriasis, pathogensis, systemic therapies

Psoriasispathogensissystemic therapies
96,581 views
29,009 downloads

Contributors:

 Rohit Kumar
,
 DP Pathak
,
 PK Sahoo
Research PaperID: AJPHR806003

Simultaneous Estimation Of Repaglinide and Metformin Hydrochloride by using RP-HPLC In Synthetic Mixture and Tablet Dosage Form

Prasanth VG, Sosamma Cicy Eapen, Prasobh Velekkat, Siyad Abdu1 Huzaifa Saeed, Khalef Ragab Gadallah

ABSTRACTAn efficient and simple RP-HPLC method has been developed and validated for simultaneous determination of Repaglinide (REPA) and Metformin Hydrochloride (MET). The separation was carried out using mobile phase consisting of Phosphate buffer: Methanol (30:70). The column was used Luna 5u C18 (2) 100A of size 0.25m *4.6mm with flow rate of 1.0 mL/min. Drug peaks were well separated and were detected by a UV detector at 260 nm.. The described method was linear over concentration range of 10-50 ppm for assay of REPA and MET. The retention time of REPA and MET was found to be 4.31. The method has been validated according to ICH guidelines with respect to system suitability, specificity, precision, accuracy, ruggedness and robustness. Metformin limit of detection (LOD) and limit of quantification (LOQ) were 0.0386 mg/ml and 0.1169mg/ml respectively while LOD and LOQ for Repaglinide were 0.0339?g/ml and 0.1025?g/ml respectively and thus can be successfully applied for the routine analysis of REPA and MET in bulk and marketed dosage forms. Keywords: Repaglinide, Metformin Hydrochloride, RP-HPLC, Simultaneous estimation, Validation

RepaglinideMetformin HydrochlorideRP-HPLCSimultaneous estimationValidation
96,786 views
29,040 downloads

Contributors:

 Prasanth VG
,
 Sosamma Cicy Eapen
,
 Prasobh Velekkat
,
 Siyad Abdu1 Huzaifa Saeed
,
 Khalef Ragab Gadallah
Research PaperID: AJPHR806004

A Perspective Approach Of Hydroxychloroquine In The Treatment for Covid-19

Sabarinath Chandrasekar, Gayathiri Muthusamy

ABSTRACTHydroxychloroquine is used in the treatment of malaria due to its pharmacological activity and with minimal adverse effects. Hydroxychloroquine is used in treatment of the diseases like rheumatoid arthritis and lupus erythematosus. In some countries, it is also indicated in the prevention or treatment of malaria. It has been developed in the 1950s from chloroquine, an old anti-malarial drug. COVID-19 is a highly contagious disease, transmitted through respiratory droplets by affected person through sneezing, coughing, talking, which also spread by touching a contaminated surface or may object. The person infected with the disease shows flu-like symptoms such as fever, muscle pain, cough and sore throat in five to six days after infection, while some patients may remain asymptomatic carriers. The disease further develops severe pneumonia in the patients. The mortality rate is high in patients with underlying conditions and those aged 60 years and above. This review complies about the mechanism, precautions, toxicity, ongoing trials of hydroxychloroquine and their medicinal usage. Keywords: Chloroquine, Clinical trials, COVID-19, Hydroxychloroquine.

ChloroquineClinical trialsCOVID-19Hydroxychloroquine.
96,850 views
29,062 downloads

Contributors:

 Sabarinath Chandrasekar
,
 Gayathiri Muthusamy
Research PaperID: AJPHR806005

Design Development and Evaluation of Perphenazine Solid Lipid Nanoparticles

Lakshith Raj P.M, Bhagawati S.T, Manjunath K, Siddesh H.M, Naveen Balaji T.S.B

ABSTRACTThe main aim of the study was to design Perphenazine solid lipid nanoparticles and to evaluate them. The Perphenazine solid lipid nanoparticles were prepared by the hot homogenization followed by ultrasonication method by using the different lipids (Tristearin, GMS, Compritol) Soya lecithin as stabilizer and Tween-80 used as surfactant. The FTIR test is conducted as the preliminary test, by this test there was no interaction between the drug and lipids. Then nanoparticles were evaluated for particle size, PDI, zeta potential, entrapment efficiency and in-vitro drug release. The particle size ranged from 53.46 to 518.6 d.nm, PDI ranged from 0.284 to 0.502, zeta potential from -9.83 to -40.96 mV and entrapment efficiency was ranged from 77.45 to 95.38%.The cumulative percentage release from all SLNs varied from 53.35 to 88.74 % after 24hours depending upon the drug and lipid ratio and F2 formulation showed highest drug release i.e., 88.74%. The release kinetic studies showed that the release first order diffusion controlled and the n value (0.47) from the Korsmeyer-Peppa’s model indicated the release mechanism was Quasi-fickian type. Keywords: Perphenazine, Solid lipid nanoparticles, FTIR, in-vitro drug release.

PerphenazineSolid lipid nanoparticlesFTIRin-vitro drug release.
97,241 views
29,234 downloads

Contributors:

 Lakshith Raj P.M
,
 Bhagawati S.T
,
 Manjunath K
,
 Siddesh H.M
,
 Naveen Balaji T.S.B